DADE BEHRING

P.O. Box 6101 Newark, DE 19714

JUL 1 1 2005

Summary of Safety and Effectiveness Information

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitter's Name:

Lorraine H Piestrak

Dade Behring Inc. P.O. Box 6101

Newark, DE 19714-6101

Date of Preparation:

April 27, 2005

Name of Product:

Dimension VistaTM Integrated system

Dimension Vista™ Urea Nitrogen Flex® reagent cartridge (BUN)

Dimension VistaTM Chemistry I Calibrator

Dimension Vista™ Immunoglobulin G Flex® reagent cartridge (IGG)

Dimension VistaTM Protein 1 Calibrator

Dimension VistaTM Protein 1 Controls, H, M, L

Dimension VistaTM Phenobarbital Flex® reagent cartridge (PHNO)

Dimension VistaTM Drug 1 Calibrator

Dimension Vista™ Mass creatine kinase MB isoenzyme Flex® reagent cartridge (MMB)

Dimension VistaTM MMB Calibrator

Dimension VistaTM V-LYTETM Integrated Multisensor (Na¹/K⁴/Cl̄)

Dimension VistaTM V-LYTETM Standard A and Standard B

FDA Classification Name:

Discrete photometric chemistry analyzer for clinical use (Class I)

Urea Nitrogen, immunoglobulin G, phenobarbital, mass creatine kinase MB isoenzyme, sodium, potassium and chloride test systems, their associated calibrators, and controls (Class II).

Predicate Device:

The following table describes the predicate devices, device classification, regulation and product code associated with this pre-market notification:

New	Predicate	Predicate	Device	Regulation	Product
Product	Device	510(k)	Class		Code
Dimension Vista TM 1500	Dimension® XL/RxL	K944093	I	862.2160	JJE
Integrated chemistry system	clinical chemistry analyzer				
Dimension Vista™ BUN	Dimension® BUN	K860021	11	862.1770	CDQ
Flex® reagent cartridge	Flex® reagent cartridge				
Dimension Vista TM	Dimension® Chem I	K860021	Π	862.1150	JIX
Chemistry I Calibrator	Calibrator				
Dimension Vista™ IGG	Dimension ® IGG	K990551	II	866.5510	CFQ
Flex® reagent cartridge	Flex® reagent cartridge				
Dimension Vista™ Protein I	N Protein Standard SL	K012470	II .	862.1150	JIX
Calibrator					
Dimension Vista™ Protein 1	N/T Protein Controls SL	K012468	H	862.1660	11.A
Controls H, M, L					
Dimension Vista™ PHNO	Dimension ® PHNO	K944932	II	862.3660	DLZ
Flex® reagent cartridge	Flex® reagent cartridge				
Dimension Vista™ Drug 1	Dimension® Drug	K011035	П	862.1150	ΊΙΧ
Calibrator	Calibrator				
Dimension Vista™ MMB	Dimension® MMB	K970343	II	862.1215	JHY
Flex® reagent cartridge	Flex® reagent cartridge				
Dimension Vista™ MMB	Dimension® MMB	K970336	Ħ	862.1150	JIT
Calibrator	Calibrator				
Dimension Vista™ V-LYTE™	Dimension® Indirect IMT	K970330	П	K -862.1600	CEM
Integrated Multisensor	system (QuikLYTE®)			Na-862.1665	JGS
Na ⁺ /K ⁺ /Cl ⁻	Na ⁺ /K ⁺ /Cl ⁻			Cl-862.1170	CGZ
Dimension VistaTM V-LYTETM	Dimension® QuikLYTE®	K860021	П	852.1150	JIT
Standard A & Standard B	Standard A & Standard B				

Device Description:

The Dade Behring Dimension VistaTM Integrated system is a floor model, fully automated, microprocessor-controlled, integrated instrument system that uses prepackaged Dade Behring Flex® reagent test cartridges to measure a variety of analytes in human body fluids. The system is a multifunctional analytical tool that processes chemical and immunochemical methodologies, utilizing photometric, turbidimetric, chemiluminesence, nephelometric, and integrated ion selective multisensor detection technologies for clinical use. The VistaTM system includes a communications and connectivity workstation (Easy LinkTM) for interaction with laboratory information system (LIS) networks, monitoring the usage of the system to suggest preventive maintenance, and QC result management.

Intended Use:

The Dade Behring Dimension VistaTM Integrated system is an *in vitro* diagnostic device intended to duplicate manual analytical procedures such as pipetting, mixing, heating, and measuring spectral intensities to determine a variety of analytes in human body fluids. VistaTM system chemical and immunochemical applications utilize photometric, turbidimetric, chemiluminescence, nephelometric and integrated ion selective multisensor technology for clinical use.

Representative Methods Intended Use:

The Urea Nitrogen Flex® reagent cartridge (BUN) is intended for the quantitative measurement of urea nitrogen (an end product of urea nitrogen metabolism) in human serum, plasma, and urine on the Dimension VistaTM system.

The Immunoglobulin G Flex® reagent cartridge (IGG) is intended for the quantitative measurement of immuoglobulin G (IgG) in human serum and plasma on the Dimension Vista™ system.

The Phenobarbital Flex® reagent cartridge (PHNO) is intended for the quantitative measurement of phenobarbital in human serum and plasma on the Dimension VistaTM system.

The Mass creatine kinase MB isoenzyme Flex® reagent cartridge (MMB) is intended for the quantitative measurement of mass creatine kinase MB isoenzyme in human serum and plasma on the Dimension VistaTM system for the confirmation of acute myocardial infarction.

The V-LYTE™ Integrated Multisensor is intended for the quantitative measurement of sodium, potassium, and chloride in human serum, plasma, and urine on the Dimension Vista™ system.

The Chemistry I calibrator is intended for the calibration of the Urea Nitrogen (BUN) method on the Dimension VistaTM system.

The Protein 1 calibrator is intended for the calibration of the Immunoglobulin G (IGG) method on the Dimension VistaTM system.

The Protein 1 controls, H, M, & L are intended for use as an assayed intralaboratory quality control for assessment of precision and analytical bias in the determination of Immunoglobulin G (IGG) results on the Dimension VistaTM system.

The Drug 1 calibrator is intended for the calibration of the Phenobarbital (PFINO) method on the Dimension VistaTM system.

The Mass CKMB Isoenzyme calibrator is intended for the calibration of the creatine kinase MB isoenzyme (MMB) method on the Dimension VistaTM system.

The V-LYTE™ Standard A & B are intended for the calibration of the Na⁺/K⁺/Cl⁻ methods on the Dimension Vista™ system.

Comparison to Predicate Device:

Both the Dimension VistaTM Integrated system and the predicate Dimension® RxL clinical chemistry system employ prepackaged reagents in flexible plastic, Dade Behring Flex® reagent cartridges. Both systems automatically process and analyze clinical samples using a variety of *in vitro* diagnostic test methods. Both systems utilize integrated, ion selective multisensor detection technology for analysis of sodium, potassium and chloride electrolytes. A comparison of the important similarities and differences of these two automated analyzer systems is provided in the following table:

Feature	Dimension Vista™ System	Dimension® RxL Analyzer
Intended Use	in vitro diagnostic use	in vitro diagnostic use
System Control	Fully automatic, microprocessor controlled	Fully automatic, microprocessor controlled
User Interface	Keyboard control Hand held barcode reader Stationary barcode scanners Graphical user interface On line help	Keyboard control Stationary barcode scanners Graphical user interface On line help
Detection Technologies	photometric turbidimetric chemiluminescence nephelometric multisensor electrodes, ion selective	photometric turbidimetric multisensor electrodes, ion selective
Reagents	Prepackaged, 12-well plastic, Dade Behring Flex® reagent cartridges, stored on board	Prepackaged, 6 & 8 well plastic, Dade Behring Flex® reagent cartridges stored on board
Calibrators	Stored on board	User places on system as needed
System fluids and Supplies	Stored on board	Stored on board
Reaction Vessels	hard plastic cuvettes & plastic reaction vessels	soft, plastic cuvettes & plastic reaction vessels
Temperature control	Reactions are controlled at 37°C Reagents are stored at 2 to 8 °C	Reactions are controlled at 37°C Reagents are stored at 2 to 8 °C
Spectral Selection	Interference filters - xenon flash lamp source	Interference filters - quartz/halogen lamp source
Test Throughput (typical)	Up to 1500 tests/hr	Up to 500 tests/hr
LIS external connectivity capability	Yes	Yes

Feature	Dimension Vista™ System	Dimension® RxL Analyzer
System Performance Monitoring	Automatic preventive maintenance (usage - based)	Traditional preventative maintenance (time-based)
Sample Level Detection Capability	Automatic	Automatic
Calibration/QC	Automatic and Manual calibration/QC	Manual calibration/QC
Sample Integrity (hemolysis, icterus, lipemia) Monitoring	Yes - spectral interference monitoring (optional)	Yes- spectral interference monitoring (optional)

Comments on Substantial Equivalence:

The automated Dade Behring Dimension® RxL and Dimension VistaTM Integrated systems are designed similarly for the same purpose. Both are floor model units that are microprocessor-controlled, integrated instrument systems that use prepackaged, Dade Behring Flex® reagent cartridges and integrated ion selective multisensor technology to analyze a variety of analytes in human body fluids. Both systems spectrally analyze processed clinical samples using chemical and immunochemical methodologies. Split sample comparative data demonstrates equivalent performance in evaluations of the representative methods.

Representative Method Comparison Data Dimension VistaTM vs. Predicate Method

Dimension Vista TM	Predicate	Sample Type		Intercept	Correlation Coefficient (r)	n
BUN	Dimension®	Serum/Plasma	1.03	0.92	0.998	111
DOIT	BUN	Urine	0.92	18.6	0.988	75
IGG	Dimension ® IGG	Serum/Plasma	0.92	1.89	0.985	98
PHNO	Dimension ® PHNO	Serum/Plasma	1.04	1.7	0.995	75
ММВ	Dimension ® MMB	Serum/Plasma	1.05	1.4	0.997	136
V-LYTETM	Dimension ®	Serum/Plasma	1.02	-1.3	0.997	103
Na [†]	QuikLYTETM Na	Urine	0.98	2.5	0.998	52
V-LYTETM	Dimension ®	Serum/Plasma	1.01	-0.06	0.999	103
K [*]	QuikLYTETM K	Urine	1.00	0.12	0.999	52
V-LYTETM	Dimension ®	Serum/Plasma	1.02	-0.3	0.998	104
CL.	QuikLYTETM CI	Urine	1.02	-3.3	0.998	51

Conclusion:

The automated Dimension® RxL and Dimension VistaTM Integrated systems are substantially equivalent in principle and performance based on the similarity of system design and split-sample comparisons using methods representative of each of the VistaTM system detection technologies. In addition, the representative test methods (BUN, IGG, PHNO, MMB, sodium, potassium and chloride) when compared to their predicates are equivalent in performance and design.

Lorraine H Piestrak

Regulatory Affairs & Compliance Manager

Mana A Roshial

April 27, 2005





JUL 1 1 2005

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Lorraine H. Piestrak Regulatory Affairs & Compliance Manager Dade Behring, Inc. Chemistry/ Immunochemistry P.O. Box 6101 Bldg 500; M.S. 514 Newark, DE 19714

Re:

k051087

Trade/Device Name: Dimension Vista™ Integrated System

Regulation Number: 21 CFR 862.1770 Regulation Name: Urea nitrogen test system

Regulatory Class: Class II

Product Code: CDQ, CEM, CFQ, CGZ, DLZ, JGS, JHY, JIT, JIX, JJY, CKA, JJE

Dated: July 1, 2005 Received: July 5, 2005

Dear Ms. Piestrak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Carol C. Benson, M.A.

Acting Director

Division of Chemistry and Toxicology

Office of In Vitro Diagnostic Device

Carol C. Benson

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

e de la companya de
510(k) Number (if known): K051087
Device Name: Dimension Vista TM Integrated System
Indications For Use:
The Dade Behring Dimension Vista TM Integrated system is an <i>in vitro</i> diagnostic device intended to duplicate manual analytical procedures such as pipetting, mixing, heating, and measuring spectral intensities to determine a variety of analytes in human body fluids. Vista TM system chemical and immunochemical applications utilize photometric, turbidimetric, chemiluminescence, nephelometric and integrated ion selective multisensor technology for clinical use.
Lorraine H Piestrak Regulatory Affairs & Compliance Manager April 27, 2005
Prescription Use AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 801)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off Office of In Vitro Diagnostic Device Page 1 of Evaluation and Safety 510(k)

510(k) Number (if known): KOSID 87
Device Name: Dimension Vista TM Urea Nitrogen Flex® reagent cartridge (BUN) Dimension Vista TM Chem I Calibrator
Indications For Use:
The Dimension Vista TM Urea Nitrogen Flex® reagent cartridge (BUN) is a device intended to measure urea nitrogen (an end-product of nitrogen metabolism) in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of certain renal and metabolic diseases.
The Dimension Vista [™] Chem I Calibrator is intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of urea nitrogen in human specimens.
Lorraine H Piestrak Regulatory Affairs & Compliance Manager April 27, 2005
Prescription Use AND/OR Over-The-Counter Use (21 CFR 801)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off
Paged of 6
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) OSIO87
CO

510(k) Number (if known): K05 1087

Device Name:	Dimension Vista TM Dimension Vista TM Dimension Vista TM	⁴ Protein I Calibra	G Flex® reagent cartridge (IGG) tor s, H, M, L
Indications For Use:			
The Dimension Vista ^{TA} consists of the reagents (serum antibody) in ser of abnormal protein me	used to measure by um and plasma. Me tabolism and the bo	easurement of immody's lack of ability	rtridge (IGG) is a device that techniques the immunoglobulin G nunoglobulin G aids in the diagnosis to resist infectious agents.
system to establish poi measurement of IgG in	nts of reference that human specimens.	are used in the de	nedical purposes for use in a test termination of values in the
The Dimension Vista ^{TI} a test system to estima arise from reagent or a	te test precision and	to detect systemat variation.	nded for medical purposes for use in the analytical deviations that may
		XIII MOUNT	e A lakel
		Lorraine ri	Affairs & Compliance Manager
Prescription Use(Part 21 CFR 801 Sub	part D)	AND/OR	Over-The-Counter Use (21 CFR 801)
(PLEASE DO NO	T WRITE BELOW	THIS LINE-CON' NEEDED)	TINUE ON ANOTHER PAGE IF
Con	currence of CDR	Office of In Vitro	Diagnostic Devices (OIVD)
ថា	vision Sign-Off	7	Page 3 of 6
	ffice of In Vitro valuation and Sa	•	vice
51	0(k) <u>05108</u>	7	
			000

510(k) Number (if known): K05/087				
Device Name: Dimension Vista TM Phenobarbital Flex® reagent cartridge (PFINO) Dimension Vista TM Drug 1 Calibrator				
Indications For Use:				
The Dimension Vista TM Phenobarbital Flex® reagent cartridge (PHNO) is a device intended to measure phenobarbital, an antiepileptic and sedative-hypnotic drug, in human serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of phenobarbital use or overdose and in monitoring levels of phenobarbital to ensure appropriate therapy.				
Dimension Vista TM Drug 1 Calibrator is intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of				
phenobarbital in human specimens. Source & Parklak				
Lorraine H Piestrak Regulatory Affairs & Compliance Manager April 27, 2005				
Prescription Use AND/OR Over-The-Counter Use (21 CFR 801)				
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)				
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)				
Division Sign-Off Page of				
Office of In Vitro Diagnostic Device Evaluation and Safety				
510(k) <u>051087</u>				

510(k) Number (if known): K05/087
Device Name: Dimension Vista™ Mass creatine kinase MB isoenzyme Flex® reagent cartridge (MMB) Dimension Vista™ MMB Calibrator
Indications For Use:
The Dimension Vista TM Mass creatine kinase MB isoenzyme Flex® reagent cartridge (MMB) is a device intended to measure the activity of the MB isoenzyme of creatine phosphokinase in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction.
The Dimension Vista™ MMB Calibrator is intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of mass creatine kinase MB isoenzyme in human specimens.
Joseph H Piestrak
Lorraine H Piestrak
Regulatory Affairs & Compliance Manager April 27, 2005
Prescription Use AND/OR Over-The-Counter Use (21 CFR 801)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off Page 5 of 6
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) <u>05/087</u>

510(k) Number:	K

(05/087

Device Name: Dimension VistaTM V-LYTETM Integrated Multisensor Nat/K+/-Cl

Dimension VistaTM V-LYTETM Standard A Dimension Vista™ V-LYTE™ Standard B

Indications For Use:

The Dimension VistaTM V-LYTE TM Sodium test system is intended to measure sodium in serum, plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.

The Dimension Vista™ V-LYTE ™ Potassium test system is intended to measure potassium in serum, plasma and urine. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions, characterized by low or high blood potassium levels.

The Dimension VistaTM V-LYTE TM Chloride test system is intended to measure chloride in serum, plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of electrolyte and metabolic disorders.

The Dimension VistaTM V-LYTE TM Standard A and Standard B are intended for medical purposes for use in a test system to establish points of reference that are used in the determination of values in the measurement of substances in human specimens. moure H Restrock

forraine H Piestrak

Regulatory Affairs & Compliance Manager

April 27, 2005

Prescription Use (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use _____ (21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Page of

Office of In Vitro Diagnostic Device **Evaluation and Safety**

510(k) <u>05108</u>7